Update on safety incident of April 27, 2025 at Lyfius Pharma Private Limited, a wholly owned subsidiary of the Company.
Awaiting price reaction for this filing.
Aurobindo Pharma provided an update on the safety incident that occurred on April 27, 2025, at its wholly owned stepdown subsidiary Lyfius Pharma Private Limited. The preliminary assessment estimates the loss at around Rs. 40 million, and the company is in the process of filing its final insurance claim. The subsidiary has submitted a renewal application for 'consent to operate' to the Andhra Pradesh Pollution Control Board (APPCB) and is awaiting approval before resuming production. Aurobindo had previously intimated the exchanges about the incident on April 28, 2025, and has committed to sharing further developments.
The estimated loss of Rs. 40 million is relatively small for Aurobindo Pharma and is likely to be covered by insurance, limiting the financial hit. However, the production halt at Lyfius remains in effect until regulatory clearance is received, which could affect output and timelines if the approval is delayed. Investors should watch for updates on the APPCB approval and resumption of operations.